Ultrafast, Ultra-Sensitive Protein Detection Method Enables Ultra-Early Disease Diagnosis
|
By LabMedica International staff writers Posted on 23 Dec 2022 |

Protein detection based on antigen–antibody reaction is vital in early diagnosis of a wide range of diseases. Methods to analyze trace amounts of proteins based on antigen–antibody reaction enable diagnosis at an early stage of many diseases, including cancer, dementia, and microbial infections. However, such methods either have limited sensitivity or require complex and time-consuming processing to allow antigen–antibody reactions to occur. Now, a team of scientists has discovered a new principle underlying light-induced acceleration of antigen–antibody reaction, allowing for simple, ultrafast, and highly sensitive detection of proteins.
Aiming to accelerate antigen–antibody reactions, the researchers at Osaka Metropolitan University (OMU, Osaka, Japan) introduced target proteins and probe particles, with modified antibodies that selectively bind to the target proteins, into a channel that is as narrow as a human hair or artery and then applied irradiation with infrared laser light for three minutes, making it possible to carry out detection at a sensitivity approximately 100 times higher than that of conventional protein testing. The researchers achieved, for the first time, the rapid measurement of trace amounts of target proteins on the order of tens of attograms (ag = 10−18 g; one quintillionth of a gram) after only three minutes of laser irradiation.
The study results demonstrate that rapid and highly sensitive detection can be achieved by condensing proteins through the simple operation of confining them in a small space and irradiating them with a laser to accelerate the reaction. These findings will facilitate the detection of disease-related substances from a small amount of body fluids, such as a single drop of blood, and will assist in the discovery of novel disease markers, potentially leading to breakthroughs in the development of systems for ultra-early diagnosis of various diseases.
“The antigen–antibody reaction is a biochemical reaction that plays a crucial role in immunity, the body’s defense function,” explained lead researcher Professor Takuya Iida, Director of the Research Institute for Light-induced Acceleration System at Osaka Metropolitan University. “In an interdisciplinary collaboration beyond physics, chemistry, and biology, we uncovered a new principle underlying the control of antigen–antibody reaction by optical force, or light-induced force. I hope that the advantage of being able to measure trace markers with high sensitivity and speed by simple laser irradiation will aid in ultra-early diagnosis.”
Related Links:
Osaka Metropolitan University
Latest Molecular Diagnostics News
- Noninvasive Urine Test Predicts Recurrence After BCG in Bladder Cancer
- Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
- Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
- cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
- Rapid Point-of-Care RT-PCR Test Differentiates Influenza A/B and SARS-CoV-2 in Minutes
- Blood-Based ctDNA Test Enhances Risk Assessment in HPV-Related Throat Cancer
- WGS MCED Assay Demonstrates Rising Sensitivity and High Specificity
- ctDNA MRD Test Identifies Breast Cancer Patients Who May Avoid Surgery
- Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
- RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
- Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
- New AI Tool Improves Detection of Genetic Causes in Rare Disorders
- Adaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
- Portable Test Uses CRISPR to Rapidly Identify STIs and Resistance Markers
- New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
- First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







